Cell therapy for hard-to-treat lupus
Treatments studied
Part of Blood & lymphatic, Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This trial tests a new type of cell therapy (YTS109 cells) for people with severe lupus that hasn't been controlled by standard treatments. The goal is to see if these cells can help calm the immune system and improve lupus symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have systemic lupus erythematosus (SLE) that hasn't improved with at least two different types of immune-suppressing medicines (like steroids, cyclophosphamide, mycophenolate, or biologics).
- You either have lupus kidney disease (lupus nephritis) with a certain level of protein in your urine, OR you have very low platelets (immune thrombocytopenia) that hasn't responded to standard treatments.
- Your blood counts, liver, kidney, and heart function are within acceptable ranges (a doctor will check this).
- You are not pregnant, breastfeeding, or planning pregnancy during the study and for 12 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new cell therapy called YTS109 for people with certain severe autoimmune diseases that have not responded to standard treatments, such as lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. The goal is to see if it can safely reduce disease activity.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases that have not responded to standard treatments. The goal is to see if it can reset the immune system and reduce disease activity in conditions like lupus, Sjögren's syndrome, and others.
This trial tests a new cell therapy called YTS109 for people with severe autoimmune diseases like lupus, Sjögren's syndrome, systemic sclerosis, inflammatory myopathy, vasculitis, and antiphospholipid syndrome. It's for those whose disease hasn't improved with standard treatments.
This trial tests a new treatment called CRC01, made from your own cells, for people with severe lupus that hasn't improved with standard medications. The goal is to see if it can safely control the disease and reduce symptoms.
This trial tests a new cell therapy called YTS109 for people with certain autoimmune diseases like lupus that have not improved with standard treatments. It aims to see if this therapy can help control disease activity.
This trial tests a new CAR-T cell treatment called Inaticabtagene Autoleucel for people with lupus that causes very low platelet counts (immune thrombocytopenia) that hasn't gotten better with standard treatments. The goal is to see if it can help raise platelet levels.
Hear when a new Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.